Systematic Review of Nasal Endoscopy Scores in Cystic Fibrosis Patients Treated With Cystic Fibrosis Transmembrane Conductance Regulator Modulators. [PDF]
Gallardo R +4 more
europepmc +1 more source
Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies after Rapid Adoption: A Dual-Approach Study. [PDF]
Miranda Afonso P +17 more
europepmc +1 more source
12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant. [PDF]
Vekaria S, Al-Abbasi H, Mulrennan S.
europepmc +1 more source
Beyond BMI: Nutritional Recovery and Functional Implications of CFTR Modulators in Cystic Fibrosis. [PDF]
Linguiti G +6 more
europepmc +1 more source
Utility of Fecal Elastase-1 in Estimating Exocrine Pancreatic Function in Cystic Fibrosis: A Scoping Review. [PDF]
Sankararaman S +3 more
europepmc +1 more source
Post-marketing safety profile of lumacaftor/ivacaftor in cystic fibrosis treatment: a pharmacovigilance analysis based on FAERS. [PDF]
Wang T +6 more
europepmc +1 more source
Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis. [PDF]
Geiger JM +6 more
europepmc +1 more source
Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]
Buniotto F +6 more
europepmc +1 more source
Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence. [PDF]
Boni A +11 more
europepmc +1 more source
Impact of COVID-19 and CFTR Modulators on Cystic Fibrosis: A Real-World Analysis of Care Patterns. [PDF]
Hinton AC +3 more
europepmc +1 more source

